Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer

The similar efficacy with acceptable safety, the ease of administration in out-patients and the economical advantages justify comparison of this oral chemotherapy with conventional intravenous chemotherapy. A randomised phase II trial is on-going in France for second-line SCLC patients on this theme.